Short answer
Esperion Therapeutics, Inc. (ESPR) filed an 8-K current report with the SEC on June 9, 2026 reporting Item 8.01 (Other Events). German antitrust clearance received effective June 2, advancing ArchiMed’s proposed acquisition.
Esperion Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- German antitrust clearance received effective June 2, advancing ArchiMed’s proposed acquisition
- Merger remains subject to HSR waiting-period expiration and Esperion stockholder approval
- Special stockholder meeting scheduled virtually for July 8, 2026 at 8:00 a.m. ET
- CVR holders face uncertainty, with payments dependent on achievement of net-sales milestones
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Esperion Therapeutics, Inc. 8-K filings
Get the next ESPR 8-K as it lands
Follow ESPR for push alerts, or ask the research agent what this filing means.